| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4191349 | Revista de Psiquiatría y Salud Mental | 2009 | 11 Pages |
Abstract
Through a probabilistic analysis, ziprasidone showed the lowest costs and the highest number of months free of psychotic symptoms and was also the most costeffective antipsychotic observed in acceptability curves and net monetary benefits.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
JoaquÃn Mould-Quevedo, Iris Contreras-Hernández, Wáscar Verduzco, Juan Manuel MejÃa-Aranguré, Juan Garduño-Espinosa,